Sells injectable osteoarthritis pain treatments and hyaluronic-acid-based regenerative products for tendon and cartilage repair to healthcare providers and commercial partners.
10-K for FY2025, filed Mar 3, 2026Osteoarthritis (“OA”) Pain Management: Orthovisc, Monovisc, and Cingal.View ↗
Monovisc and Orthovisc are our single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions.…View ↗
Regenerative Solutions: Integrity, Hyalofast, and Tactoset.View ↗
Integrity is an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments. It is designed to protect…View ↗
Hyalofast is a 100% HA resorbable scaffold used for single stage cartilage regeneration. While Tactoset and Integrity are commercialized…View ↗
As a result of these distinctions, we employ multiple sales models in the United States to ensure that we meet the needs of our customers…View ↗
The company sells products to OEM partners and distributors, with sales occurring when products ship; hospital and surgery-center sales occur when products are implanted. Some partner arrangements also generate royalties tied to end-customer sales.
10-K for FY2025, filed Mar 3, 2026For commercial partnership sales, the Company sells its products directly to these partners, who perform most of the downstream sales and…View ↗
For sales to hospitals and ASCs, which generally pair in-house sales representatives with local or regional distributors, the inventory is…View ↗
For distributor sales, the Company sells its products principally to distributors, generally outside the United States, who subsequently…View ↗
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by product or service ↗$112.8M
10-K for FY2025, filed Mar 3, 2026
$112.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
OEM Channel
Mix
10-K for FY2025, filed Mar 3, 2026 |
57%
FY2022: 72%
|
OEM Channel, FY2025
$64.4M Sources
|
Mix |
|
Commercial Channel
Sold outright
10-K for FY2025, filed Mar 3, 2026 |
43%
FY2022: 28%
|
Commercial Channel, FY2025
$48.4M Sources
|
Sold outright |
J&J MedTech handles U.S. sales of Monovisc and Orthovisc to end customers. Anika sells regenerative products directly to clinicians, hospitals and surgery centers in the U.S., and sells internationally through distributors.
10-K for FY2025, filed Mar 3, 2026Monovisc and Orthovisc are our single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions.…View ↗
As a result of these distinctions, we employ multiple sales models in the United States to ensure that we meet the needs of our customers…View ↗
In the U.S., we sell our Regenerative Solutions portfolio directly to clinicians, including hospitals and ASCs, through a hybrid approach…View ↗
Outside of the United States, we market and sell our products using a worldwide network of commercial distributors, providing a solid…View ↗
10-K for FY2025, filed Mar 3, 2026
The Company’s largest such customer, Johnson & Johnson MedTech (“J&J MedTech”) (previously known as DePuy Synthes Mitek Sports Medicine), a…View ↗
Not on paper. It lost $10.9M in FY2025, but brought in more cash than it spent: $4.4M of free cash flow.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$311KView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
Shrinking. Revenue fell 24% in 4 years, from $147.8M in FY2021 to $112.8M in FY2025, about 7% a year.
A narrower product focus
The older report describes sports medicine and bone-preserving joint solutions alongside its HA products; the latest focuses on OA pain management and regenerative solutions after selling Parcus Medical and Arthrosurface.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 3, 2026In early 2020, we expanded our overall technology platform, product portfolio, and significantly expanded our commercial infrastructure…View ↗
Beginning in 2020, we launched our transformational strategy to diversify our revenue in the global joint preservation markets, expanding…View ↗
Sports Medicine. Our line of soft tissue repair solutions is used by surgeons to repair and reconstruct damaged ligaments and tendons…View ↗
Arthrosurface Joint Solutions. Our portfolio of more than 150 bone preserving joint solutions, including partial joint replacement, joint…View ↗
Competes with Sanofi Genzyme, Zimmer Biomet, Bioventus, Avanos Medical, Pacira BioSciences, Conmed, Ferring Pharmaceuticals, Arthrex, Smith & Nephew, Stryker, Atreon Orthopedics, and Bone Support
10-K for FY2025, filed Mar 3, 2026We compete with numerous companies, including large pharmaceutical firms and specialized medical device companies, across our product…View ↗
Loading...